Skip to main content

Gene Expression Abnormalities in Thymoma

Buy Article:

$68.00 + tax (Refund Policy)

Thymoma is one of the most common solid tumors in the mediastinum. The histological classification of thymic epithelial tumor includes non-invasive thymoma, invasive thymoma and rare thymic carcinomas. Although several clinico-pathological and immunological studies of thymoma have been reported, little is known of the genetic alterations that occur in the tumorigenesis of thymoma. In this review, we would mention about several gene expression abnormalities in thymoma, including (1) p53, which is mutationally inactivated in many tumors; (2) matrixmetalloproteinases (MMPs), that may play important roles in tumor invasion and metastasis; (3) Epidermal growth factor receptor (EGFR), which is important in normal and neoplastic epithelial cell growth and is an attractive therapeutic target, as reviewed recently; and (4) genes at chromosome 6, which suffers frequent and multiple aberrations in thymoma. Finally, using oligonucleotide arrays to monitor in vivo gene expression levels in the early and late stage thymoma tissues, two candidate genes were identified that were more highly expressed in the advanced stage thymomas. One was a wellknown gene, c-JUN and another was an unknown gene, AL050002.

Keywords: chromosome 6; egfr; mmp; p53; thymoma

Document Type: Review Article

Affiliations: Department of Surgery II, Nagoya City University Medical School, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.

Publication date: 01 December 2003

More about this publication?
  • Current Pharmacogenomics provides comprehensive overviews of all current research on pharmacogenomics and pharmacogenetics. All areas of the field from pre-clinical to clinical research are covered, including related areas such as genomics, proteomics, target discovery, bioinformatics and novel diagnostics. This international journal is peer-reviewed and publishes both mini- and full review articles.

    The journal has become essential reading for all researchers and clinicians with interests in pharmacogenomics and pharmacogenetics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content